Solara Active Pharma Sciences Limited has informed the Exchange about Credit Rating
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
CRISIL Ratings has reviewed Solara Active Pharma Sciences' bank loan facilities of Rs. 1,484 crore. The long-term rating has been reaffirmed at CRISIL BBB with the outlook revised from 'Negative' to 'Stable', a positive change. The short-term rating has been reaffirmed at CRISIL A3+. The bank facilities include cash credit, letter of credit, long-term loans from lenders like HDFC Bank, ICICI Bank, YES Bank, RBL Bank, IDFC First Bank, and Aditya Birla Finance, along with a proposed working capital facility of Rs. 563 crore. The outlook revision signals improved confidence in the company's near-term financial health and debt repayment capability.
The outlook upgrade from Negative to Stable is a constructive signal for shareholders, indicating CRISIL's improved view on the company's financial stability and ability to service its debt. This should be viewed positively by the market, though the underlying BBB rating remains unchanged (investment grade, lower medium grade).